Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-11

AUTHORS

Hans R Hendriks, Anne-Sophie Govaerts, Iduna Fichtner, Sally Burtles, Andrew D Westwell, Godefridus J Peters

ABSTRACT

BACKGROUND: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in vivo testing of potential anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell screen. METHODS: Over a period of more than twenty years the EORTC-Cancer Research Campaign panel reviewed ∼2000 compounds of which 95 were selected for further evaluation. Selected compounds were stepwise developed with clear go/no go decision points using a pharmacologically directed programme. RESULTS: This approach eliminated quickly compounds with unsuitable pharmacological properties. A few compounds went into Phase I clinical evaluation. The lessons learned and many of the principles outlined in the paper can easily be applied to current and future drug discovery and development programmes. CONCLUSIONS: Changes in the review panel, restrictions regarding numbers and types of compounds tested in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation of the European NCI programme in 2017 and its transformation into an academic platform of excellence for anticancer drug discovery and development within the EORTC-PAMM group. This group remains open for advice and collaboration with interested parties in the field of cancer pharmacology. More... »

PAGES

195

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2017.167

DOI

http://dx.doi.org/10.1038/bjc.2017.167

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085995929

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28609434


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Discovery", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "European Union", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "National Cancer Institute (U.S.)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Hendriks Pharmaceutical Consulting, J. Wagenaarstraat 67, Purmerend 1443 LR, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hendriks", 
        "givenName": "Hans R", 
        "id": "sg:person.01300125274.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300125274.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "EORTC, Avenue E. Mounier 83/11, Brussels 1200, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Govaerts", 
        "givenName": "Anne-Sophie", 
        "id": "sg:person.01335265251.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335265251.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Max Delbr\u00fcck Center for Molecular Medicine", 
          "id": "https://www.grid.ac/institutes/grid.419491.0", 
          "name": [
            "Max-Delbr\u00fcck Center for Molecular Medicine, Robert-R\u00f6ssle-Str. 10, Berlin-Buch 13125, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fichtner", 
        "givenName": "Iduna", 
        "id": "sg:person.0777701322.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777701322.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "Queen Mary, University of London, Mile End Road, London E1 4NS, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burtles", 
        "givenName": "Sally", 
        "id": "sg:person.01007371475.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007371475.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiff University", 
          "id": "https://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Westwell", 
        "givenName": "Andrew D", 
        "id": "sg:person.01060276475.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060276475.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Secretary EORTC-PAMM group, Laboratory Medical Oncology, VU University Medical Centre, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "Godefridus J", 
        "id": "sg:person.01255301342.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/7.suppl_4.s105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006117512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007166971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-540-47648-1_2786", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008028405", 
          "https://doi.org/10.1007/978-3-540-47648-1_2786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000425827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010823231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000425827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010823231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011985678", 
          "https://doi.org/10.1038/nrd2155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011985678", 
          "https://doi.org/10.1038/nrd2155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(12)70022-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014616745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1179/joc.2007.19.1.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020661032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.2001.1796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026993418", 
          "https://doi.org/10.1054/bjoc.2001.1796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1541-7786.mcr-16-0090", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029710188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0024-3205(95)00254-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030845361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/anie.201510610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032752915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/anie.201510610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032752915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/anie.201510610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032752915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/anie.201510610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032752915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2003.11.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036593387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000425829", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038737533"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000425829", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038737533"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/b:brea.0000041586.64371.88", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042920996", 
          "https://doi.org/10.1023/b:brea.0000041586.64371.88"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2613.2002.00211.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046175030"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm070834t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055951405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm070834t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055951405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm900968s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055956686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm900968s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055956686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008207304355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056302588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1017195517099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056308206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/81.14.1088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059815226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/82.18.1457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059816019"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/0929867043455530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069160336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076135763", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076598670", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076989478", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077487252", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082639650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083092102", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-11", 
    "datePublishedReg": "2017-07-11", 
    "description": "BACKGROUND: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in vivo testing of potential anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell screen.\nMETHODS: Over a period of more than twenty years the EORTC-Cancer Research Campaign panel reviewed \u223c2000 compounds of which 95 were selected for further evaluation. Selected compounds were stepwise developed with clear go/no go decision points using a pharmacologically directed programme.\nRESULTS: This approach eliminated quickly compounds with unsuitable pharmacological properties. A few compounds went into Phase I clinical evaluation. The lessons learned and many of the principles outlined in the paper can easily be applied to current and future drug discovery and development programmes.\nCONCLUSIONS: Changes in the review panel, restrictions regarding numbers and types of compounds tested in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation of the European NCI programme in 2017 and its transformation into an academic platform of excellence for anticancer drug discovery and development within the EORTC-PAMM group. This group remains open for advice and collaboration with interested parties in the field of cancer pharmacology.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2017.167", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "117"
      }
    ], 
    "name": "Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative", 
    "pagination": "195", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c73f94581a6b4e961aed7246bcac332183a73aad8932a84c39f461478ecec7b4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28609434"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2017.167"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085995929"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2017.167", 
      "https://app.dimensions.ai/details/publication/pub.1085995929"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000434.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2017167"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2017.167'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2017.167'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2017.167'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2017.167'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      64 URIs      28 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2017.167 schema:about N00021fc170a2412caa2fa3a0fa746c77
2 N0de7d7879e474f7385668d76745bb222
3 N2cdf069fadb647329238ab5f77b13525
4 N6149fd58d812461bb26ff3b73eadccdf
5 N9263805985344801bd92601209cff03c
6 N965a043ac6ca4d7d8c330b13e331d6d5
7 Naa098f451d264334813dc81974814fe4
8 Nc5c7b73d95ef414db275a0b4d78868c3
9 anzsrc-for:11
10 anzsrc-for:1115
11 schema:author N370c0c15f4c64d8b922cc6d6c05c5755
12 schema:citation sg:pub.10.1007/978-3-540-47648-1_2786
13 sg:pub.10.1023/b:brea.0000041586.64371.88
14 sg:pub.10.1038/nrd2155
15 sg:pub.10.1054/bjoc.2001.1796
16 https://app.dimensions.ai/details/publication/pub.1076135763
17 https://app.dimensions.ai/details/publication/pub.1076598670
18 https://app.dimensions.ai/details/publication/pub.1076989478
19 https://app.dimensions.ai/details/publication/pub.1077487252
20 https://app.dimensions.ai/details/publication/pub.1083092102
21 https://doi.org/10.1002/anie.201510610
22 https://doi.org/10.1016/0024-3205(95)00254-4
23 https://doi.org/10.1016/j.ejca.2003.11.022
24 https://doi.org/10.1016/s1359-6349(12)70022-8
25 https://doi.org/10.1021/jm070834t
26 https://doi.org/10.1021/jm900968s
27 https://doi.org/10.1023/a:1008207304355
28 https://doi.org/10.1023/a:1017195517099
29 https://doi.org/10.1046/j.1365-2613.2002.00211.x
30 https://doi.org/10.1093/annonc/7.suppl_4.s105
31 https://doi.org/10.1093/jnci/81.14.1088
32 https://doi.org/10.1093/jnci/82.18.1457
33 https://doi.org/10.1093/oxfordjournals.annonc.a058872
34 https://doi.org/10.1158/1078-0432.ccr-08-0138
35 https://doi.org/10.1158/1541-7786.mcr-16-0090
36 https://doi.org/10.1159/000425827
37 https://doi.org/10.1159/000425829
38 https://doi.org/10.1179/joc.2007.19.1.66
39 https://doi.org/10.2174/0929867043455530
40 schema:datePublished 2017-07-11
41 schema:datePublishedReg 2017-07-11
42 schema:description BACKGROUND: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in vivo testing of potential anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell screen. METHODS: Over a period of more than twenty years the EORTC-Cancer Research Campaign panel reviewed ∼2000 compounds of which 95 were selected for further evaluation. Selected compounds were stepwise developed with clear go/no go decision points using a pharmacologically directed programme. RESULTS: This approach eliminated quickly compounds with unsuitable pharmacological properties. A few compounds went into Phase I clinical evaluation. The lessons learned and many of the principles outlined in the paper can easily be applied to current and future drug discovery and development programmes. CONCLUSIONS: Changes in the review panel, restrictions regarding numbers and types of compounds tested in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation of the European NCI programme in 2017 and its transformation into an academic platform of excellence for anticancer drug discovery and development within the EORTC-PAMM group. This group remains open for advice and collaboration with interested parties in the field of cancer pharmacology.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf Na6f61906fca44617835334e44a00c110
47 Ndc0a65a0f73a4b23801d7b2f288d5d52
48 sg:journal.1017082
49 schema:name Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
50 schema:pagination 195
51 schema:productId N2587868567ee4b5bb4b7ecce2e85568d
52 N2e98688665be4714afd32f4b10f5a1f3
53 N8c66a94142f64644b96fca3e9573162c
54 N973af88b7b474411a0a8a5de1be0acd7
55 Nf0df69e8025d46ceb540d979b33a8ebc
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085995929
57 https://doi.org/10.1038/bjc.2017.167
58 schema:sdDatePublished 2019-04-10T21:25
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N5e8be5a24e3a4d559b09865ad8b4c437
61 schema:url https://www.nature.com/articles/bjc2017167
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N00021fc170a2412caa2fa3a0fa746c77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name United States
67 rdf:type schema:DefinedTerm
68 N0ce46a4e10df41c092b7461477f42c96 rdf:first sg:person.01060276475.95
69 rdf:rest Nbe15938c4f454020b6ea996176040abc
70 N0de7d7879e474f7385668d76745bb222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name National Cancer Institute (U.S.)
72 rdf:type schema:DefinedTerm
73 N2587868567ee4b5bb4b7ecce2e85568d schema:name doi
74 schema:value 10.1038/bjc.2017.167
75 rdf:type schema:PropertyValue
76 N2cdf069fadb647329238ab5f77b13525 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Antineoplastic Agents
78 rdf:type schema:DefinedTerm
79 N2e98688665be4714afd32f4b10f5a1f3 schema:name readcube_id
80 schema:value c73f94581a6b4e961aed7246bcac332183a73aad8932a84c39f461478ecec7b4
81 rdf:type schema:PropertyValue
82 N370c0c15f4c64d8b922cc6d6c05c5755 rdf:first sg:person.01300125274.36
83 rdf:rest N9b490676b5034ba9bd6a889f039fc29d
84 N437deaafebd04bbc9dc82f37ca1018bc schema:name Hendriks Pharmaceutical Consulting, J. Wagenaarstraat 67, Purmerend 1443 LR, The Netherlands
85 rdf:type schema:Organization
86 N5e8be5a24e3a4d559b09865ad8b4c437 schema:name Springer Nature - SN SciGraph project
87 rdf:type schema:Organization
88 N605a62cbb25f40f6affe7461027e519c rdf:first sg:person.01007371475.29
89 rdf:rest N0ce46a4e10df41c092b7461477f42c96
90 N6149fd58d812461bb26ff3b73eadccdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Drug Discovery
92 rdf:type schema:DefinedTerm
93 N81bfccd968ff4fcd97d9230a4e6ff723 rdf:first sg:person.0777701322.49
94 rdf:rest N605a62cbb25f40f6affe7461027e519c
95 N8c66a94142f64644b96fca3e9573162c schema:name pubmed_id
96 schema:value 28609434
97 rdf:type schema:PropertyValue
98 N9263805985344801bd92601209cff03c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Neoplasms
100 rdf:type schema:DefinedTerm
101 N965a043ac6ca4d7d8c330b13e331d6d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name European Union
103 rdf:type schema:DefinedTerm
104 N973af88b7b474411a0a8a5de1be0acd7 schema:name dimensions_id
105 schema:value pub.1085995929
106 rdf:type schema:PropertyValue
107 N9b490676b5034ba9bd6a889f039fc29d rdf:first sg:person.01335265251.89
108 rdf:rest N81bfccd968ff4fcd97d9230a4e6ff723
109 Na6f61906fca44617835334e44a00c110 schema:issueNumber 2
110 rdf:type schema:PublicationIssue
111 Naa098f451d264334813dc81974814fe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Research
113 rdf:type schema:DefinedTerm
114 Nbe15938c4f454020b6ea996176040abc rdf:first sg:person.01255301342.17
115 rdf:rest rdf:nil
116 Nc5c7b73d95ef414db275a0b4d78868c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 Ndc0a65a0f73a4b23801d7b2f288d5d52 schema:volumeNumber 117
120 rdf:type schema:PublicationVolume
121 Nf0df69e8025d46ceb540d979b33a8ebc schema:name nlm_unique_id
122 schema:value 0370635
123 rdf:type schema:PropertyValue
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
128 schema:name Pharmacology and Pharmaceutical Sciences
129 rdf:type schema:DefinedTerm
130 sg:journal.1017082 schema:issn 0007-0920
131 1532-1827
132 schema:name British Journal of Cancer
133 rdf:type schema:Periodical
134 sg:person.01007371475.29 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
135 schema:familyName Burtles
136 schema:givenName Sally
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007371475.29
138 rdf:type schema:Person
139 sg:person.01060276475.95 schema:affiliation https://www.grid.ac/institutes/grid.5600.3
140 schema:familyName Westwell
141 schema:givenName Andrew D
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060276475.95
143 rdf:type schema:Person
144 sg:person.01255301342.17 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
145 schema:familyName Peters
146 schema:givenName Godefridus J
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17
148 rdf:type schema:Person
149 sg:person.01300125274.36 schema:affiliation N437deaafebd04bbc9dc82f37ca1018bc
150 schema:familyName Hendriks
151 schema:givenName Hans R
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300125274.36
153 rdf:type schema:Person
154 sg:person.01335265251.89 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
155 schema:familyName Govaerts
156 schema:givenName Anne-Sophie
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335265251.89
158 rdf:type schema:Person
159 sg:person.0777701322.49 schema:affiliation https://www.grid.ac/institutes/grid.419491.0
160 schema:familyName Fichtner
161 schema:givenName Iduna
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777701322.49
163 rdf:type schema:Person
164 sg:pub.10.1007/978-3-540-47648-1_2786 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008028405
165 https://doi.org/10.1007/978-3-540-47648-1_2786
166 rdf:type schema:CreativeWork
167 sg:pub.10.1023/b:brea.0000041586.64371.88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042920996
168 https://doi.org/10.1023/b:brea.0000041586.64371.88
169 rdf:type schema:CreativeWork
170 sg:pub.10.1038/nrd2155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011985678
171 https://doi.org/10.1038/nrd2155
172 rdf:type schema:CreativeWork
173 sg:pub.10.1054/bjoc.2001.1796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026993418
174 https://doi.org/10.1054/bjoc.2001.1796
175 rdf:type schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1076135763 schema:CreativeWork
177 https://app.dimensions.ai/details/publication/pub.1076598670 schema:CreativeWork
178 https://app.dimensions.ai/details/publication/pub.1076989478 schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1077487252 schema:CreativeWork
180 https://app.dimensions.ai/details/publication/pub.1083092102 schema:CreativeWork
181 https://doi.org/10.1002/anie.201510610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032752915
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/0024-3205(95)00254-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030845361
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/j.ejca.2003.11.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036593387
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s1359-6349(12)70022-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014616745
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1021/jm070834t schema:sameAs https://app.dimensions.ai/details/publication/pub.1055951405
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1021/jm900968s schema:sameAs https://app.dimensions.ai/details/publication/pub.1055956686
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1023/a:1008207304355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056302588
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1023/a:1017195517099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056308206
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1046/j.1365-2613.2002.00211.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046175030
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1093/annonc/7.suppl_4.s105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006117512
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1093/jnci/81.14.1088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059815226
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1093/jnci/82.18.1457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059816019
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1093/oxfordjournals.annonc.a058872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082639650
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1158/1078-0432.ccr-08-0138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007166971
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1158/1541-7786.mcr-16-0090 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029710188
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1159/000425827 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010823231
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1159/000425829 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038737533
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1179/joc.2007.19.1.66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020661032
216 rdf:type schema:CreativeWork
217 https://doi.org/10.2174/0929867043455530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069160336
218 rdf:type schema:CreativeWork
219 https://www.grid.ac/institutes/grid.16872.3a schema:alternateName VU University Medical Center
220 schema:name Secretary EORTC-PAMM group, Laboratory Medical Oncology, VU University Medical Centre, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.418936.1 schema:alternateName European Organisation for Research and Treatment of Cancer
223 schema:name EORTC, Avenue E. Mounier 83/11, Brussels 1200, Belgium
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.419491.0 schema:alternateName Max Delbrück Center for Molecular Medicine
226 schema:name Max-Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, Berlin-Buch 13125, Germany
227 rdf:type schema:Organization
228 https://www.grid.ac/institutes/grid.5600.3 schema:alternateName Cardiff University
229 schema:name School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.83440.3b schema:alternateName University College London
232 schema:name Queen Mary, University of London, Mile End Road, London E1 4NS, UK
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...